ArticleCureus2026
Impact of COVID-19 on Movement Disorders Patients in the Outpatient Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The coronavirus disease 2019 (COVID-19) pandemic may have been the only worldwide infectious outbreak that many patients have experienced in their lifetime. The impact of COVID-19 on patients with chronic neurodegenerative disease, including movement disorders, is largely unknown. Since patients with movement disorders rely heavily on inpatient therapies and are closely followed by their medical team, it would be reasonable to see an increase in stress during a period of prolonged isolation. This study aimed to determine the emotional impact, stress, and burden of the COVID-19 pandemic on patients with movement disorders in an academic practice. Methods Over four months during the COVID-19 pandemic, from May 2021 to August 2021, patients with movement disorders were screened for eligibility to participate in the study conducted at a single academic center. Patients must be at least 18 years of age, diagnosed with a movement disorder by an academic physician who specializes in movement disorders, and score ≥ 24 on the mini-mental state exam (MMSE). Patients would be excluded if they were not able to speak or read English or scored <24 on the MMSE, indicating cognitive impairment. Study participants were asked to fill out a subjective questionnaire (the COVID-19 and Movement Disorders Questionnaire [CMDQ]) asking whether neurological symptoms, relationships, mental health care, finances, or healthcare delays worsened during the COVID-19 pandemic. Patients were also tested on the Pandemic Emotional Impact Scale (PEIS), a validated instrument designed to measure the emotional impact of a worldwide pandemic on populations within the United States, and the Patient Health Questionnaire (PHQ-4). Results The mean PEIS score for the cohort was 32.52 ± 12.61 (range 16-80). Higher (worse) PEIS scores were significantly associated with "personal financial loss" (p=0.0077), "worsening neurological symptoms" (p=0.0006), "strained relationships" (p=0.0021), "friends/family experiencing financial loss" (p=0.0006), "friends/family hospitalized" (p=0.0178), "delay in healthcare" (p < 0.0001), and "masks impacting health" (p = 0.0064). The mean PHQ-4 score was 3.18 (mild distress), and over 30% of the population were positive for symptoms of anxiety. Conclusion Although the emotional burden of COVID-19 was low in this cohort, patients were affected by financial burdens, strained relationships, delays in healthcare, and mask-wearing. More research is needed to assess the potential long-term effects of COVID-19 on these individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.